摘要
目的观察辛伐他汀、阿托伐他汀、瑞舒伐他汀与替格瑞洛联用后是否存在药物相互作用。方法选择急性冠脉综合征患者,随机分为单用辛伐他汀、阿托伐他汀、瑞舒伐他汀组及这3种药分别与替格瑞洛联合用药组,2周后测定各组血清尿酸、转氨酶水平、低密度脂蛋白水平、血小板聚集率,并随访2个月,比较临床疗效及不良事件发生率是否存在差异。结果与单用他汀组比较,联合用药组在低密度脂蛋白水平上差异无统计学意义,血小板聚集率明显降低,而尿酸水平、转氨酶水平差异没有统计学意义。不良事件中,联合用药组与单用他汀组相比不良事件发生率差异无统计学意义。结论治疗剂量下的辛伐他汀、阿托伐他汀与替格瑞洛联用对疗效及不良反应发生率改变不显著。瑞舒伐他汀与替格瑞洛之间不存在影响。
AIM To observe whether there existed drug-drug interactions between simvastatin, atorvastatin, rosuvastatin combined with ticagrelor. METHODS Acute coronary syndrome patients were randomly assigned to simvastatin, atorvastatin and rosuvastatin groups and ticagrelor in combination with simvastatin, atorvastatin and rosuvastatin groups. The levels of uric acid, aminotransferase, low density lipoprotein-cholesterol and the rate of platelet aggregation were measured. All patients were followed up for 2 months to compare whether there was a difference in the clinical efficacy and the incidence of adverse events. RESULTS Compared with use alone statins,there was no significant difference in blood low density lipoprotein-cholesterol levels. Platelet aggregation rate decreased significantly in the groups of ticagrelor combined with statins. There was no significant difference in the levels of uric acid and aminotransferase. There was also no significant difference in the incidence of adverse events between the combined use of drugs and statins alone. CONCLUSION The therapeutic dose in common use are not expected to affect the clinical curative effect and adverse reactions occurred rate in the short-term. There is no effect between rosuvastatin and ticagrelor, so the combination can be assured.
出处
《中国临床药学杂志》
CAS
2017年第1期28-31,共4页
Chinese Journal of Clinical Pharmacy
基金
江门市科技局科研基金(编号2015102)
